Imaging Early Response to Checkpoint Inhibition.

Abstract

Immune checkpoint blockade therapy has achieved remarkable clinical success, but these promising results have been limited to a minority of patients. Thus far, efforts to establish a predictive biomarker or accurately assess early response to treatment have been fruitless. In this issue of <i>Cancer Research</i>, Saida and colleagues utilized advanced molecular imaging modalities to assess changes in the tumor microenvironment that correlate with tumor response to immune checkpoint blockade therapy <i>in vivo</i> This study suggests a combination of imaging biomarkers with potential for delineating clinical response to immunotherapy.<i>See related article by Saida et al., p. 3693</i>.